Biogen reported a second Phase II success for litifilimab in cutaneous lupus erythematosus (CLE), reinforcing BDCA2 as a therapeutic target in refractory disease. The company said the latest readout supports the targeted approach in patients who have limited options, with Biogen positioning litifilimab as a potential first-in-class therapy for CLE. CLE has traditionally been managed largely with antimalarials, glucocorticoids, and other repurposed immunomodulators. Biogen’s strategy would shift treatment toward a more specific mechanism centered on BDCA2 and targeted immune modulation. If later studies confirm efficacy and durability, Biogen’s CLE program could become a meaningful competitive differentiator in immunodermatology, where targeted options remain constrained for the skin-limited lupus population.